Retrospective Study to Analyze the Efficacy and Safety of Trabectedin and Pegylated Liposomal Doxorubicin (PLD ) in the Treatment of Patients With Platinum-sensitive Recurrent Ovarian Cancer (ROC), According to SmPC
Retrospective Study to Analyze the Efficacy and Safety of Trabectedin and Pegylated Liposomal Doxorubicin (PLD ) in the Treatment of Patients With Platinum-sensitive Recurrent Ovarian Cancer (ROC), According to SmPC.
Ovarian Epithelial Cancer Recurrent
DRUG: Trabectedin and Pegylated Liposomal Doxorubicin
Efficacy progression-free survival (PFS), Describe the impact of trabectedin - pegylated liposomal doxorubicin combination of retreatment with platinum ROC, in terms of progression-free survival ( PFS)., Up to 12 months|Overall survival (OS), Describe the impact of trabectedin - pegylated liposomal doxorubicin combination of retreatment with platinum ROC, in terms of overall survival (OS ) ., Up to 12 months
Response rate to previous and post-treatment (Percentage of responses (CR+PR), Percentage of responses (CR+PR) at pretreatment and post-treatment, Up to 12 months|Response rate to trabectedin - DLP combination (Percentage of responses (CR+PR), Percentage of responses ( CR + PR ) to trabectedin - DLP, Up to 12 months|Clinical Benefit in 4 months (Percentage of clinical benefit (CR + PR + SD), Percentage of clinical benefit (CR + PR + SD for at least 4 months), Up to 12 months|Impact of trabectedin - PLD combination in subsequent treatments, Assessment of the impact of treatment with trabectedin - PLD combination at the beginning of subsequent treatments, Up to 12 months|Toxicity (adverse events), type , incidence , severity, frequency, severity and relationship to the treatment of adverse events reported in patients reports, Up to 12 months|Comparison between PFS and PFS2, Comparison of the PFS of prior platinum combination TRB + DLP and subsequent platinum PFS., Up to 12 months|Hypersensitivity and allergic reactions (Number and Management of hypersensitivity reactions or allergies), Number and Management of hypersensitivity reactions or allergies., Up to 12 months
Retrospective Study to Analyze the Efficacy and Safety of Trabectedin and Pegylated Liposomal Doxorubicin (PLD ) in the Treatment of Patients With Platinum-sensitive Recurrent Ovarian Cancer (ROC), According to SmPC.